Actively Recruiting
PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
Led by NYU Langone Health · Updated on 2025-10-10
60
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity than MRI alone for identifying recurrence or failure in patients undergoing focal therapy.
CONDITIONS
Official Title
PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male patients 40-95 years of age with biopsy-confirmed localized prostate cancer
- Grade Group 652 (Gleason score 3+4 or higher)
- Unifocal disease visible on multiparametric MRI
- Undergoing High-Intensity Focused Ultrasound (HIFU) as part of standard care
- PSA less than 20 ng/mL
- No metastatic disease on PSMA PET/CT
- Willing to follow-up with PSA testing, imaging, and biopsies
You will not qualify if you...
- Evidence of metastatic disease on PSMA PET/CT
- Allergy to POSLUMA or gadolinium
- Unable to tolerate MRI due to claustrophobia or posture/back-hip problems
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
Research Team
M
Majlinda Tafa
CONTACT
W
Wei Phin Tan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here